Advertisement

The Relationship Between Myostatin, Inflammatory Markers, and Sarcopenia in Patients With Chronic Kidney Disease

Published:February 02, 2022DOI:https://doi.org/10.1053/j.jrn.2022.01.011

      Objective

      To determine the prevalence of sarcopenia in patients with chronic kidney disease (CKD), investigate the relationship of the serum myostatin level with sarcopenia and inflammatory markers.

      Methods

      The study was conducted with four patient groups: renal transplantation (TX), stage 3-5 non–dialysis-dependent CKD (NDD-CKD), hemodialysis (HD), and peritoneal dialysis (PD). Laboratory parameters, serum myostatin, C-reactive protein, and interleukin-6 levels were studied. Body composition was estimated using a multifrequency bioimpedance analysis. Handgrip strength (HGS) was evaluated with a handgrip dynamometer. The HGS and appendicular skeletal muscle index measurements were used to determine sarcopenia presence.

      Results

      The study included 130 patients (72 [55%] male patients). The patient distribution in groups was as follows: 37 in HD, 28 in PD, 37 in renal TX, and 28 in NDD-CKD. The highest level of myostatin was measured in the HD group, and the lowest in the TX group (P < .001). The HGS measurement in the PD group was significantly lower than that in the TX group (P = .025). The myostatin was negatively correlated with HGS, albumin, estimated glomerular filtration rate, and Kt/Vurea. However, myostatin had no correlation with inflammatory markers or appendicular skeletal muscle index. Sarcopenia was present in 37 (29%) patients: 15 (40%) in the HD group, nine (32%) in NDD-CKD, seven (25%) in PD, and six (16%) in TX. When the patients with and without sarcopenia were compared, only myostatin was higher in the former (P = .045). As a result of multivariate analysis, myostatin was the only independent factor which predicts sarcopenia (odds ratio: 1.002, 95% confidence interval: 1.001-1.005, P = .048).

      Conclusion

      To prevent devastating events associated with sarcopenia in patients with CKD, renal transplantation seems to be the best treatment solution. For the early recognition of sarcopenia, the measurement of the serum myostatin level may be a promising diagnostic approach.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Renal Nutrition
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cruz-Jentoft A.J.
        • Bahat G.
        • Bauer J.
        • et al.
        Sarcopenia: revised European consensus on definition and diagnosis.
        Age Ageing. 2019; 48: 16-31
        • Fahal I.H.
        Uraemic sarcopenia: aetiology and implications.
        Nephrol Dial Transpl. 2014; 29: 1655-1665
        • Wang X.H.
        • Mitch W.E.
        Mechanisms of muscle wasting in chronic kidney disease.
        Nat Rev Nephrol. 2014; 10: 504-516
        • Ikizler T.A.
        • Hakim R.M.
        Nutrition in end-stage renal disease.
        Kidney Int. 1996; 50: 343-357
        • Pereira R.A.
        • Cordeiro A.C.
        • Avesani C.M.
        • et al.
        Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality.
        Nephrol Dial Transpl. 2015; 30: 1718-1725
        • Lai S.
        • Muscaritoli M.
        • Andreozzi P.
        • et al.
        Sarcopenia and cardiovascular risk indices in patients with chronic kidney disease on conservative and replacement therapy.
        Nutrition. 2019; 62: 108-114
        • Pedersen B.K.
        • Febbraio M.A.
        Muscles, exercise and obesity: skeletal muscle as a secretory organ.
        Nat Rev Endocrinol. 2012; 8: 457-465
        • Verzola D.
        • Procopio V.
        • Sofia A.
        • et al.
        Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease.
        Kidney Int. 2011; 79: 773-782
        • Enoki Y.
        • Watanabe H.
        • Arake R.
        • et al.
        Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1.
        Sci Rep. 2016; 6: 32084
        • Boras E.
        • Slevin M.
        • Alexander M.Y.
        • et al.
        Monomeric C-reactive protein and Notch-3 co-operatively increase angiogenesis through PI3K signalling pathway.
        Cytokine. 2014; 69: 165-179
        • Zhang L.
        • Pan J.
        • Dong Y.
        • et al.
        Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass.
        Cell Metab. 2013; 18: 368-379
        • Zhang L.
        • Rajan V.
        • Lin E.
        • et al.
        Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease.
        Faseb j. 2011; 25: 1653-1663
        • Garibotto G.
        • Sofia A.
        • Procopio V.
        • et al.
        Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: effects of end-stage renal disease and microinflammatory state.
        Kidney Int. 2006; 70: 384-390
        • Daugirdas J.T.
        Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error.
        J Am Soc Nephrol. 1993; 4: 1205-1213
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Levin A.
        • Stevens P.E.
        • Bilous R.W.
        • et al.
        Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.
        Kidney Int supplements. 2013; 3: 1-150
        • Foley R.N.
        • Wang C.
        • Ishani A.
        • Collins A.J.
        • Murray A.M.
        Kidney function and sarcopenia in the United States general population: NHANES III.
        Am J Nephrol. 2007; 27: 279-286
        • Lee Y.L.
        • Jin H.
        • Lim J.Y.
        • Lee S.Y.
        Relationship between low handgrip strength and chronic kidney disease: KNHANES 2014-2017.
        J Ren Nutr. 2021; 31: 57-63
        • Zhou Y.
        • Hellberg M.
        • Svensson P.
        • Höglund P.
        • Clyne N.
        Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3-5.
        Nephrol Dial Transpl. 2018; 33: 342-348
        • Hiraki K.
        • Yasuda T.
        • Hotta C.
        • et al.
        Decreased physical function in pre-dialysis patients with chronic kidney disease.
        Clin Exp Nephrol. 2013; 17: 225-231
        • Dierkes J.
        • Dahl H.
        • Lervaag Welland N.
        • et al.
        High rates of central obesity and sarcopenia in CKD irrespective of renal replacement therapy - an observational cross-sectional study.
        BMC Nephrol. 2018; 19: 259
        • Rossi A.P.
        • Zaza G.
        • Zanardo M.
        • et al.
        Assessment of physical performance and body composition in male renal transplant patients.
        J Nephrol. 2018; 31: 613-620
        • Blumenkrantz M.J.
        • Gahl G.M.
        • Kopple J.D.
        • et al.
        Protein losses during peritoneal dialysis.
        Kidney Int. 1981; 19: 593-602
        • Markaki A.
        • Kyriazis P.
        • Dermitzaki E.K.
        • et al.
        The association between handgrip strength and predialysis serum Sodium level in patients with chronic kidney disease stage 5D.
        Front Med (Lausanne). 2020; 7: 610659
        • Qureshi A.R.
        • Alvestrand A.
        • Danielsson A.
        • et al.
        Factors predicting malnutrition in hemodialysis patients: a cross-sectional study.
        Kidney Int. 1998; 53: 773-782
        • Guida B.
        • Maro M.D.
        • Lauro M.D.
        • et al.
        Identification of sarcopenia and dynapenia in CKD predialysis patients with EGWSOP2 criteria: an observational, cross-sectional study.
        Nutrition. 2020; 78: 110815
        • Kim C.
        • Kim J.K.
        • Lee H.S.
        • Kim S.G.
        • Song Y.R.
        Longitudinal changes in body composition are associated with all-cause mortality in patients on peritoneal dialysis.
        Clin Nutr. 2021; 40: 120-126
        • Gil A.P.P.
        • Lunardi A.C.
        • Santana F.R.
        • et al.
        Impact of renal transplantation and immunosuppressive therapy on muscle strength, functional Capacity, and Quality of Life: a Longitudinal study.
        Transpl Proc. 2020; 52: 1279-1283
        • Kalantar-Zadeh K.
        • Kopple J.D.
        Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients.
        Am J Kidney Dis. 2001; 38: 1343-1350
        • Stenvinkel P.
        • Alvestrand A.
        Inflammation in end-stage renal disease: sources, consequences, and therapy.
        Semin Dial. 2002; 15: 329-337
        • Kaizu Y.
        • Ohkawa S.
        • Odamaki M.
        • et al.
        Association between inflammatory mediators and muscle mass in long-term hemodialysis patients.
        Am J Kidney Dis. 2003; 42: 295-302
        • Marini A.C.
        • Motobu R.D.
        • Freitas A.T.V.
        • Laviano A.
        • Pimentel G.D.
        Pre-sarcopenia in patients undergoing hemodialysis: prevalence and association with biochemical parameters.
        Clin Nutr ESPEN. 2018; 28: 236-238
        • Tay L.
        • Ding Y.Y.
        • Leung B.P.
        • et al.
        Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults.
        Age (Dordr). 2015; 37: 121
        • Han D.S.
        • Chen Y.M.
        • Lin S.Y.
        • et al.
        Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis.
        Clin Endocrinol (Oxf). 2011; 75: 857-863
        • Yano S.
        • Nagai A.
        • Isomura M.
        • et al.
        Relationship between blood myostatin levels and kidney function:Shimane CoHRE study.
        PLoS One. 2015; 10: e0141035
        • Morishita Y.
        • Kubo K.
        • Haga Y.
        • et al.
        Skeletal muscle loss is negatively associated with single-pool Kt/V and dialysis duration in hemodialysis patients.
        Ther Apher Dial. 2014; 18: 612-617
        • Crossland H.
        • Constantin-Teodosiu D.
        • Greenhaff P.L.
        • Gardiner S.M.
        Low-dose dexamethasone prevents endotoxaemia-induced muscle protein loss and impairment of carbohydrate oxidation in rat skeletal muscle.
        J Physiol. 2010; 588: 1333-1347
        • Caldiroli L.
        • Armelloni S.
        • Eskander A.
        • et al.
        Association between the uremic toxins indoxyl-sulfate and p-cresyl-sulfate with sarcopenia and malnutrition in elderly patients with advanced chronic kidney disease.
        Exp Gerontol. 2021; 147: 111266
        • As'habi A.
        • Najafi I.
        • Tabibi H.
        • Hedayati M.
        Prevalence of sarcopenia and dynapenia and their Determinants in Iranian peritoneal dialysis patients.
        Iran J Kidney Dis. 2018; 12: 53-60
        • Yanishi M.
        • Kimura Y.
        • Tsukaguchi H.
        • et al.
        Factors associated with the development of sarcopenia in kidney transplant Recipients.
        Transpl Proc. 2017; 49: 288-292